Scientific Platforms

We’re here to make an impact. At Ocugen, we approach drug development with a sense of urgency, resolve, ingenuity, and boldness. We consider patients in everything we do. Courageous innovation means driving science in new directions and breaking new ground.

PIPELINE

PRECLINICAL
IND
PHASE 1
PHASE 2
PHASE 3
  • Asset/ Program
    OCU400

    AAV-hNR2E3
    Received orphan drug designations

    Indication

    Treatment of NR2e3, RHO
    and CEP290 Mutations

    Phase

    Phase 1/2

    Phase 1/2
  • Asset/ Program
    OCU410

    AAV-hRORA

    Indication

    Dry Age-Related Macular Degeneration (Dry AMD)

    Phase

    Phase 1/2

    Phase 1/2
  • Asset/ Program
    OCU410ST

    AAV-hRORA

    Indication

    Stargardt (orphan disease)

    Phase

    Phase 1/2

    Phase 1/2
  • Asset/ Program
    OCU200

    Transferrin-Tumstatin

    Indication

    Diabetic Macular Edema, Diabetic Retinopathy and Wet Age-Related Macular Degeneration (Wet AMD)

    Phase

    IND Submitted*

    IND Submitted*
  • Asset/ Program
    NeoCart®

    (Autologous chondrocyte-derived neocartilage)

    Indication

    Treatment of Articular Cartilage Defects in the Knee

    Phase

    Phase 3**

    Phase 3**
  • Asset/ Program
    OCU500

    Bivalent inhaled vaccine

    Indication

    For Prevention of Disease Caused by COVID-19

    Phase

    IND Planned***

    IND Planned***
  • Asset/ Program
    OCU510

    Quadrivalent inhaled vaccine

    Indication

    For Prevention of Disease Caused by Flu

    Phase

    IND Planned

    IND Planned
  • Asset/ Program
    OCU520

    Combination quadrivalent flu and bivalent COVID-19 inhaled vaccine

    Indication

    For Prevention of Disease Caused by Flu and COVID-19

    Phase

    IND Planned

    IND Planned

*Waiting for FDA clearance before initiating Phase 1 trial
**Phase 3 Clinical Trial planned for 2H 2024
***OCU500 IND planned for early 2024 in collaboration with NIAID